To Get more Insights,  Request A Free Sample 

Market Dynamics

Driver: Rising Prevalence of Blood Disorders and Chronic Diseases

Chile’s dynamic immunohematology market growth is being driven by the dramatic rise in blood diseases. In only a decade, lymphoblastic leukemia has grown 27% with around 1,500 new cases each year. What is most startling is that now leukemia is the most common cancer among Chilean children under 15 years old accounting for one quarter of all new cancer diagnoses in the country. Acute lymphocytic leukemia (ALL) represents 75% of childhood and teenage cases; chronic lymphocytic leukaemia (CLL) is prevalent among adults over 19 years old making up 38% of adult diagnosis.

Hemophilia has one of Latin America’s highest figures with over 4,000 people affected in Chile alone. In addition, Von Willebrand Disease (VWD) affects about 1% or an estimated number close to 190 thousand persons within the country’s population. Another major public health problem is anemia which affects 20.8% of women at reproductive age and a staggering 51.7 % among pregnant women mainly due to iron deficiency.

Cardiovascular conditions related to blood disorders also contribute towards driving the immunohematology market further upwards. People carrying A, B, or AB antigen types are at higher risk factor for heart attack secondary to coronary artery disease when compared against those with O type blood group whose chances are considered average . Additionally, certain groups of clots forming more frequently based on their blood types might mean increased occurrence rates leading into cardiovascular events within Chilean communities where these findings were discovered. Ischemic strokes account for most cases presenting as cerebrovascular accidents recorded during surveys conducted across different parts from countrywide setting – this condition often correlates with abnormal clotting tendency but not hemorrhagic stroke which occurs less frequently.

Apart from these there are other cancers involving blood such as lymphomas and multiple myeloma that should be looked into within the immunohematology market due to their rising prevalence rates within Chile. Although sickle cell disease is less common in Chile than other regions, it still affects around 0.1 % of the population especially among people with African ancestry. Additionally, thalassemia carrierships which form about 2-3 % of the general populace also contributes towards expanding the range blood related disorders responsible for promoting business growth opportunities linked with immunohematological activities in this country.

Trend: Adoption of Automated Immunohematology Technologies

The Chilean healthcare sector is seeing a major change with the adoption of automated immunohematology technologies aimed at boosting operational efficiency in hospitals and laboratories, reducing human errors, and enhancing patient safety. The suppliers in the immunohematology market have been receiving high demands for their latest automated solutions that are transforming how blood banks and transfusion services operate in the country. For example, the Chilean Red Cross has turned to Ortho Vision automated immunohematology analyzer which is installed in most facilities operating under it as the largest blood bank network in Chile. This technology can be used to do blood typing for up to 60 samples per hour besides screening for antibodies with high throughput while being accurate enough such that results will always be correct thus saving time taken during tests.

Furthermore, many hospitals and diagnostic laboratories around Chile have started preferring automation instruments which integrate several functions onto one platform. This shift is growing markets because workers can now see how they could make their work easier by automating some parts thus improving efficiency throughout workflow as well reducing labor costs alongside ensuring better quality control over outputs achieved through machines.

Accordingly, with these new state-of-the-art automated solutions adopted by Chilean laboratories not only does it increase its own operational efficiency but also ensures timely availability for safe compatible blood products hence leading to better patient outcomes.

Challenge: Limited Awareness and Expertise in Immunohematology

The Chilean immunohematology market is being held back by low awareness and understanding of immunohematology. This is especially true for developing nations and disadvantaged communities. One major issue is that people do not know about or understand advanced immunohematologic products and services. A recent study conducted by the Chilean Society of Hematology found that this was the case among just 35% of healthcare workers in rural areas, compared to 68% in cities. Such a difference in knowledge could deny some patients access to good quality blood products thereby affecting their outcomes.

Another challenge in the immunohematology market is lack of enough specialists trained in immunohematology. As at mid-2022, The National Training and Employment Service (SENCE) reported a yearly deficit of 6,000 IT experts in Chile alone; while only 1,200 registered technicians specialized across all regions nationwide according 2023 data from the Chilean Association of Clinical Laboratory Professionals (ACCLP). Smaller provincial hospitals may have difficulty with testing accuracy during transfusions if they don’t have enough qualified staff as well as other associated procedures such as compatibility matching.

Segmental Analysis

By Product

The reagent segment dominates Chile's immunohematology market, experiencing the highest CAGR of 4.76% and holding the largest share of 55.31%. Technological advancements in immunohematology testing have resulted in more accurate and efficient reagents which has led to their need. There is an upsurge in blood disorders like leukemia, haemophilia and anaemia hence extensive tests are required thus increasing demand for reagents. Blood transfusions have risen by 15% over five years indicating a growing need for immunohematology reagents. Initiatives aimed at expanding blood banks coupled with increased awareness on the importance of immunohaematological testing have also fueled demand for these products.

Automated analyzers used during immunhemosyologic testing necessitate compatible reagents because they improve precision as well as efficiency thereby raising demand levels for them too. The government’s investments in healthcare infrastructure such as $500 million set aside for modernizing healthcare facilities including those dealing with blood transfusion services will boost reagent sales further. The burden posed by chronic diseases requires frequent monitoring through use of immuno-haematological tests thus increasing consumption rates of these materials significantly. Immunohemo-logical screening needs good quality antibodies therefore thoroughness in ensuring safety brings about higher standards met by having excellent-quality antigens used alongside them.

More money spent on health care enables end users in the immunohematology market purchase better performing diagnostic tools together with corresponding consumable kits like reagent packs hence contributing to overall growth within this industry segment. In line with this, ongoing investigations into different aspects concerning immune haemotology testing are yielding positive results leading onto production new types or brands of such supplies necessary for various types of tests demanded over time. Also, adherence to strict rules governing safe bloods is one other factor responsible behind increased demand for high quality reagent. Demographic shifts brought about by population ageing combined with changes in patterns of diseases will also impact on the need for immunohaematologic investigations and consequently consumption levels of re-agents used during these tests.

By Technology

Microplates accounted for 35.46% of all Chile’s immunohematology market share due to adaptability for different tests including ABO system analysis, Rh phenotype determination and antibody screening. Healthcare providers like them because they can measure many samples at once. They are cheap to make compared with other technologies and easy too. For example, this year gel cards costed $1.20 per test on average while biochips went for $2.50 but microplates only needed $0.50 per test in 2022. In addition, they do well with automated analyzers that are increasingly becoming widespread in use within the country hence making it a good option since also most tests done last year were using such systems than any other years.

Microplates also enable large volume processing through high-throughput testing by laboratories, which greatly reduces turnaround time as one single 96-well plate can process up-to 96 tests simultaneously. It has been an old technology that has been used over decades. Thus, its reliability cannot be doubted upon. As demand grows even more in the Chille immunohematology market due to increased number of people requiring blood transfusion services every year especially in Chile where figures reached 320000 (15% increase from 2017), immuno-haematological tests demand will continue rising.

The EMT sub-segment under Immunohematology market is projected to grow at the highest CAGR of 5.82% in Chile. The global rise in cases of leukemia and other blood cancers have driven the demand for effective treatments worldwide which includes EMT. Scientists have come up with new methods that involve looking at compatibility between recipients’ and donors’ blood samples outside human bodies called vitro studies as a diagnostic tool among many others thus contributing significantly towards making this area grow rapidly. Serological testing numbers have surged lately because more people are contracting various diseases especially those related to their bloods hence forth increasing usage rates for PCR therefore affecting closely allied fields such as EMT.

By Application

The Chilean immunohematology market is dominated by the antibody screening segment at 50.96% in 2023 and this position will continue to grow at a CAGR of 4.85% during the forecast period because of multiple factors. First, more frequent blood transfusion and organ transplant procedures call for accurate detection of antibodies to ensure compatibility between donors and recipients hence preventing adverse reactions. Secondly, as the number of people living with chronic diseases like leukemia goes up so does the need for screening antibodies which is crucial in-patient care management in such cases. Also, there have been increased efforts towards pre-transfusion testing awareness creation coupled with an emphasis on safety from patients’ points of view thereby driving demand within different healthcare setups. Moreover, it is noted that this service heavily relies upon detecting antibodies since many elderly individuals within Chile may require transfusions or interventions frequently due to their age bracket among other factors.

Apart from this, the Chille immunohematology market witnessing a significant growth in the screening due to stringent regulation concerning blood transfusions and transplants that require every facility dealing with these processes to include antibody screening protocols into its system. Hence, ensuring they become common practice everywhere they are applicable. Otherwise, failure to comply may lead not only legal action but also public condemnation where necessary precautions were not taken leading to infection transmission which could have been easily prevented through proper use of available resources. Furthermore, advanced molecular serological methods have been incorporated within various stages involved in carrying out effective screening process including those done outside laboratory settings. Thereby, increasing accuracy level achieved while obtaining results thus building trust among users affected thereby eventually propelling business growth associated with such activities related to this area.

By End Use

In Chile’s immunohematology market, the hospitals are holding over 40.62% market share and is projected to grow at the highest CAGR of 5% in the years to come. There has been an increase in demand for blood transfusions and immunohematology tests within hospitals. There has been a surge in need for blood transfusion services and comprehensive immunohematology care units within hospitals driven by the increased number of surgical operations conducted; treatments given to patients suffering from chronic diseases as well as those seeking emergency medical attention.

Also, there are more cases of haematological disorders among patients admitted into different health facilities which necessitates provision of these services in such settings. The integration of advanced immunohematology technologies and practices is critical towards enhancing patient care within healthcare systems while striving for their safety hence underscoring this sectors’ significant market share coupled with its rapid growth rate. Another factor contributing to its growth is Personalized Medicine approach where precision medicine becomes paramount thus leading to use such kind of treatment approaches at a large scale.

Hospitals  in the immunohematology market are equipped with strong infrastructure and resources needed for the efficient execution of immunohematology processes such as blood typing, crossmatching and investigation of immune mediated hemolysis among others which ensures dominance in the market as well as rapid expansion. Additionally, stringent regulations about transfusion safety coupled with quality assurance requirements applicable across all hospital-based blood transfusion services acted as catalysts towards increased adoption rates for more sophisticated immunohematologic techniques thereby giving hospitals an upper hand in terms of market share growth. 

 To Understand More About this Research:  Request A Free Sample 

Recent Developments

• In Sep 2023, Abbott partners with mAbxience Holdings S.L. to distribute biosimilars for oncology, women's health, and respiratory diseases in emerging markets. Initial launches slated for 2025, with additional molecules pending clinical development. Abbott expands access in Latin America, Southeast Asia, the Middle East, and Africa with its broad presence.
• In May 2023, Beckman Coulter launched the DxI 9000 Access Immunoassay Analyzer, boasting the highest productivity per footprint, capable of running up to 215 tests per hour per square meter.

Key Players in the Chile Immunohematology Market

• Abbott Laboratories
• Beckman Coulter, Inc.
• Becton, Dickinson, and Company
• Bio-Rad Laboratories, Inc.
• Grifols
• Immucor
• QuidelOrtho Corporation
• Siemens Healthcare GmbH
• Sysmex Corporation
• Thermo Fisher Scientific
• Other Prominent Players

Market Segmentation Overview:

By Products

• Analyzers
  • Automatic Analyzers
  • Semi-automatic/Non-automatic Analyzers
• Reagents
  • Blood Typing Reagents
  • Antibody Screening Reagents
  • Compatibility Testing Reagents
  • Other Reagents

By Technology

• Biochips
• Gel Cards
• Microplates
• PCR
• Erythrocyte-magnetized Technology

By Application

• Antibody Screening
• Blood Typing
• Others

By End Use

• Hospitals
• Diagnostic Laboratories
• Blood Banks
• Academic and Research Institutes